Active Biotech AB - Interim report January - September 2017

2017-11-09

The company's application related to one of the patent families in the SILC project was granted patent in the US

Preclinical data for a SILC substance was published in the scientific journal Cancer Immunology Research

The process to divest the company's research facility at Ideon in Lund has been initiated, for further comments related to the company's liquidity situation see the section "Outlook, including significant risks and uncertainties"